Evidence map›Paper›PMID 42427159›Full record

ReviewAlzheimer's & dementia : the journal of the Alzheimer's Association2026

Safety considerations of gene-based therapies for Alzheimer's disease.

Elizabeth A Bevins, Gabriel C Léger, Michelle A Herman, John M Ringman, Subhojit Roy, Matthew Shtrahman, Judy Pa, Howard H Feldman

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Elizabeth A BevinsAlzheimer's Disease Cooperative Study (ADCS), University of California San Diego, La Jolla, California, USA.ORCID https://orcid.org/0009-0007-9306-9435
Gabriel C LégerAlzheimer's Disease Cooperative Study (ADCS), University of California San Diego, La Jolla, California, USA.ORCID https://orcid.org/0000-0001-7900-3957
Michelle A HermanAlzheimer's Disease Cooperative Study (ADCS), University of California San Diego, La Jolla, California, USA.ORCID https://orcid.org/0009-0001-0187-213X
John M RingmanAlzheimer's Disease Research Center, Department of Neurology, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.ORCID https://orcid.org/0000-0001-5429-0777
Subhojit RoyDepartment of Neurosciences, University of California San Diego, La Jolla, California, USA.ORCID https://orcid.org/0000-0002-1571-2735
Matthew ShtrahmanDepartment of Neurosciences, University of California San Diego, La Jolla, California, USA.ORCID https://orcid.org/0000-0003-3185-890X
Judy PaAlzheimer's Disease Cooperative Study (ADCS), University of California San Diego, La Jolla, California, USA.ORCID https://orcid.org/0000-0002-5788-9352
Howard H FeldmanAlzheimer's Disease Cooperative Study (ADCS), University of California San Diego, La Jolla, California, USA.ORCID https://orcid.org/0000-0002-9258-4538

Funding

Epstein Family Alzheimer's Research Collaboration (EFARC)
6 · The paper itself

Abstract

Gene-based therapies show increasing promise for the treatment of neurologic disease. In 2016, nusinersen, an RNA-based therapy, was approved for children with spinal muscular atrophy (SMA). Over 200 clinical trials have utilized gene therapy approaches for a host of neurodegenerative and neuromuscular disorders, including Alzheimer's disease (AD).

Indexed as

Alzheimer DiseaseGenetic TherapyAnimalsDependovirusGene Therapy AgentsHumansOligonucleotides, AntisenseOligonucleotides, AntisenseAAVadeno‐associated virusAlzheimer's diseasecentral nervous systemclinical trialsgene‐based therapygene therapygenetic mutationmedical safetymedical safety datamild cognitive impairmentneurodegenerative diseaseneurodegenerative disordersneurotoxicitysafety and risk assessment

Identifiers

PMID42427159
PMCPMC13351316

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.